Profile
Charlotta Gauffin is currently Chief Scientific Officer at Dicot Pharma AB since 2022.
Former positions include Head-Clinical Trial Management at LIDDS AB from 2019 to 2022, and Manager-Clinical Project & Program Director at Medivir AB, Biovitrum AB, and Galderma Holding AB. Education includes graduate and doctorate degrees from the University of Uppsala.
Charlotta Gauffin active positions
| Companies | Position | Start |
|---|---|---|
| DICOT PHARMA AB | Chief Tech/Sci/R&D Officer | 2022-07-10 |
Former positions of Charlotta Gauffin
| Companies | Position | End |
|---|---|---|
| LIDDS AB | Chief Tech/Sci/R&D Officer | 2022-06-30 |
Galderma Holding AB | Chief Tech/Sci/R&D Officer | - |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Chief Tech/Sci/R&D Officer | - |
| MEDIVIR AB | Chief Tech/Sci/R&D Officer | - |
Training of Charlotta Gauffin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Medivir AB
Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Commercial Services |
University of Uppsala
University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LIDDS AB
LIDDS AB Pharmaceuticals: MajorHealth Technology Focuses on the development of treatment alternatives and hormonal therapy for prostate cancer | Health Technology |
Galderma Holding AB | |
Dicot Pharma AB
Dicot Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs to treat erectile failure | Health Technology |
- Stock Market
- Insiders
- Charlotta Gauffin
















